ReciGen

From Wikipedia, the free encyclopedia

ReciGen is the trade name of recombinant Interferon beta 1-a, which is manufactured as biosimilar as a liquid biomedicine in Iran.

Description

ReciGen is a type of Interferon beta which is used for multiple sclerosis (MS) therapy. Multiple sclerosis is the most common disease of the central nervous system. ReciGen is a glycoprotein and a Cytokine. Interferon beta-1a is a 22,500 Da glycoprotein, which has antiviral activity and regulates the immune system of the human body. This product is made by recombinant technology and categorised as biomedicime and bosimilar. The amino acid sequence of this protein is the same as natural beta interferon. Both of these two proteins are glycosilated.

Indication

Recigen is used for treatment of relapsing-remitting form of multiple sclerosis.

Drug form & dosage

ReciGen is available as ready to inject liquid in 1 ml syringe which is filled with 0.5 ml of liquid medicine. Each dose contains 44 micrograms of active protein which is equal to 12 million international unit of activity. Recigen should be injected subcutaneous.

References

  • Drug insert of ReciGen, populated by CinnaGen Co.

External links

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.